India`s largest drugmaker Sun Pharmaceutical Industries Ltd posted a first-quarter profit on Tuesday, beating street estimates, helped by stronger sales in the United States.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Net profit came in at 9.83 billion rupees ($140.6 million) for the three months ended June 30, compared with a loss of 4.25 billion rupees a year earlier, the company said https://www.bseindia.com/xml-data/corpfiling/AttachLive/7fb22856-27f5-4c....

In the year-ago quarter, Sun Pharma incurred costs of 9.51 billion rupees related to settlements in a U.S. antitrust case over sleep disorder drug Modafinil.

Analysts on average expected a net profit of 8.97 billion rupees. Sales from its U.S. formulations business, which constitutes over a third of total sales, grew 8 percent from the previous corresponding quarter. Sales of branded formulations in India rose 22 percent as the implementation of a nation-wide Goods and Services Tax (GST) impacted sales last year.

Total revenue from operations rose about 16 percent to 72.24 billion rupees.

WATCH ZEE BUSINESS VIDEO HERE

Smaller rivals Lupin Ltd reported a fall in June-quarter net profit earlier, hurt by declining U.S. sales while Cipla Ltd posted a better-than-expected quarterly profit on the back of strong domestic sales.

Sun Pharma stock jumped nearly 8 percent after the results. It was the top percentage gainer on the broader Mumbai market that was up 0.73 percent.

($1 = 69.9300 Indian rupees)